Phase
Condition
Urologic Cancer
Prostate Cancer
Prostate Cancer, Early, Recurrent
Treatment
AAA817
Investigators choice of SoC
Clinical Study ID
Ages 18-100 Male
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria: ∙
adults ≥ 18 years of age.
ECOG performance status of 0 to 2.
histopathological and/or cytological confirmation of adenocarcinoma of the prostate.
PSMA-positive disease as assessed by PSMA PET/CT scan using an approved PSMA imagingagent as protocol instructed,
castrate level of serum/plasma testosterone (< 50 ng/dL or < 1.7 nmol/L).
Prior treatments with an androgen receptor pathway inhibitor (ARPI) and taxane-basedchemotherapy, and progressed on or after [177Lu]Lu-PSMA targeted therapy.
≥ 1 metastatic lesion that is present on screening/baseline CT, MRI, or bone scanimaging obtained ≤ 28 days prior to randomization
eGFR as requested by the sponsor
Exclusion
Exclusion Criteria:
Any investigational agents within 28 days prior to the day of randomization.
Any 225Ac-based investigational compound used prior to the day of randomization.
Participants with a history of CNS metastases who are neurologically unstable,symptomatic, or receiving corticosteroids for the purpose of maintaining neurologicintegrity.
Concurrent acute kidney injury (renal failure developed between 48 hours to 7 days)or chronic kidney disease (at least 3 months of ongoing renal injury)
Baseline xerostomia ≥ Grade 2 by CTCAE v.5
History of uncontrolled hypertension, myocardial infarction (MI), angina pectoris,or coronary artery bypass graft (CABG) within 6 months prior to ICF signature and/orclinically active significant cardiac disease
History of lymphoproliferative disease or any known malignancy or history ofmalignancy of any organ system within the past 5 years (except for basal cellcarcinoma or actinic keratosis that have been treated with no evidence of recurrencein the past 3 months, non-invasive malignant colon polyps that have been removed).
Other protocol-defined inclusion/exclusion criteria may apply.
Study Design
Study Description
Connect with a study center
Novartis Investigative Site
Singapore, 168583
SingaporeActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.